Acurx Pharmaceuticals

Antibiotics typically face stewardship constraints and payer pressure. While brand fidaxomicin’s WAC is high, generic fidaxomicin is now marketed in the U.S., compressing class pricing and access dynamics.

Any pricing power for ibezapolstat would need to be justified by clear reductions in recurrence and total cost of care, potentially displacing adjuncts like bezlotoxumab or microbiome therapeutics. Until pivotal data demonstrate such advantages and payers accept them, sustainable pricing leverage is limited.